terazosin has been researched along with fiduxosin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brune, ME; Hancock, AA; Katwala, SP; Kerwin, JF; Meyer, MD; Milicic, I; Williams, M; Witte, DG | 1 |
1 review(s) available for terazosin and fiduxosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for terazosin and fiduxosin
| Article | Year |
|---|---|
Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Heterocyclic Compounds, 3-Ring; Male; Phenylephrine; Prazosin; Prostate; Pyrimidinones; Regional Blood Flow; Sulfonamides; Tamsulosin; Urethra | 2002 |